ATE550662T1 - Diagnose- und behandlungsverfahren sowie dafür geeignete mittel - Google Patents

Diagnose- und behandlungsverfahren sowie dafür geeignete mittel

Info

Publication number
ATE550662T1
ATE550662T1 AT02753953T AT02753953T ATE550662T1 AT E550662 T1 ATE550662 T1 AT E550662T1 AT 02753953 T AT02753953 T AT 02753953T AT 02753953 T AT02753953 T AT 02753953T AT E550662 T1 ATE550662 T1 AT E550662T1
Authority
AT
Austria
Prior art keywords
aberrant
diagnosis
appropriate means
treatment procedures
cell
Prior art date
Application number
AT02753953T
Other languages
English (en)
Inventor
Jane Visvader
Geoffrey Lindeman
Eleanor Sum
Lorraine O'reilly
Original Assignee
Inst Medical W & E Hall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Medical W & E Hall filed Critical Inst Medical W & E Hall
Application granted granted Critical
Publication of ATE550662T1 publication Critical patent/ATE550662T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
AT02753953T 2001-09-12 2002-09-12 Diagnose- und behandlungsverfahren sowie dafür geeignete mittel ATE550662T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR761801 2001-09-12
PCT/AU2002/001246 WO2003023404A1 (en) 2001-09-12 2002-09-12 A method of diagnosis and treatment and agents useful for same

Publications (1)

Publication Number Publication Date
ATE550662T1 true ATE550662T1 (de) 2012-04-15

Family

ID=3831521

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02753953T ATE550662T1 (de) 2001-09-12 2002-09-12 Diagnose- und behandlungsverfahren sowie dafür geeignete mittel

Country Status (8)

Country Link
US (1) US7700271B2 (de)
EP (1) EP1436624B1 (de)
JP (1) JP4628674B2 (de)
AT (1) ATE550662T1 (de)
AU (1) AU2002322199B2 (de)
CA (1) CA2460092C (de)
NZ (1) NZ569653A (de)
WO (1) WO2003023404A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9815877B2 (en) 2012-06-07 2017-11-14 The Children's Hospital Of Philadelphia Controlled gene expression methods
CN109979526B (zh) * 2014-03-25 2023-11-24 凡弗3基因组有限公司 用于功能证实癌症突变的rna分析的系统和方法
CN116999454A (zh) * 2023-08-22 2023-11-07 苏泽杰 基于LMO4基因干扰逆转耐阿霉素Luminal A型乳腺癌的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
AUPP713498A0 (en) 1998-11-17 1998-12-10 Chandler, Howard Milne A method of detecting blood
EP1234185B1 (de) * 1999-11-29 2008-07-09 Beth Israel Deaconess Medical Center Pin1 als stadiumsmarker der aggressivität und/oder der metastasierung abnormale zellwachstum
CA2432639A1 (en) * 2000-11-16 2002-05-23 Cemines, Llc Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease
AU2002950778A0 (en) 2002-08-15 2002-09-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland A method of characterizing dendritic cells
JP5339676B2 (ja) 2003-02-21 2013-11-13 メドベット サイエンス ピーティーワイ． リミテッド 細胞を検出する方法、およびこれに有用な薬剤

Also Published As

Publication number Publication date
JP4628674B2 (ja) 2011-02-09
EP1436624B1 (de) 2012-03-21
WO2003023404A8 (en) 2003-05-08
AU2002322199B2 (en) 2009-06-04
US7700271B2 (en) 2010-04-20
WO2003023404A1 (en) 2003-03-20
EP1436624A1 (de) 2004-07-14
NZ569653A (en) 2011-03-31
JP2005502066A (ja) 2005-01-20
CA2460092A1 (en) 2003-03-20
EP1436624A4 (de) 2005-05-25
CA2460092C (en) 2013-05-21
US20050048528A1 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
EA200600452A1 (ru) Автоматизированные способы и системы для обнаружения и анализа сосудистых бляшек
DE60228557D1 (de) Candida-nachweis
ATE515575T1 (de) Verfahren und sonden für den nachweis von krebs
DK1439897T3 (da) Fremgangsmåder til adskillelse af sjældne celler fra væskeprøver
ATE474228T1 (de) Reagenz für hämoglobinabbau
ZA200202942B (en) Elisa for VEGF.
WO2005012553A3 (en) Optical in vivo probe of analyte concentration within the sterile matrix under the human nail
EE05675B1 (et) Meetod konformse haiguse diagnoosimiseks v?i tuvastamiseks, selleks vajalik katsemenetlus, reaktiivikomplekt ning seade
TW200512298A (en) Method of diagnosing breast cancer
AU4694499A (en) Trace level detection of analytes using artificial olfactometry
WO2004031410A3 (en) Method for diagnosing testicular seminomas
EP1563300A4 (de) Diagnoseverfahren für sprue/zeliakie
DK1421215T3 (da) Fremgangsmåder til evaluering af patologiske tilstande under anvendelse af ekstracellulært RNA
EP2287618A3 (de) Verfahren zur Diagnose neurodegenerativer Erkrankungen
PL354423A1 (en) Method of biological fluid sampling and making corresponding analyte measurements as well as an electrochemical cell, apparatus and system therefor
WO2006036744A3 (en) Methods for a global assay of coagulation and fibrinolysis
WO2007013575A3 (en) Method for diagnosing and treating renal cell carcinoma
EP1543331A4 (de) Verfahren zur diagnose von morbus alzheimer
ATE514948T1 (de) In vitro verfahren zur diagnose von neurodegenerativen erkrankungen
GB0420774D0 (en) Wound treatment system
NZ599813A (en) Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders
ATE550662T1 (de) Diagnose- und behandlungsverfahren sowie dafür geeignete mittel
EP1392719A4 (de) Formen prostataspezifischer antigene und verfahren zu deren nachweis
WO2005005957A3 (en) Method of detecting cancer using delta-catenin
FI990380A7 (fi) Diagnostinen ja seulontamenetelmä